Johnson & Johnson Stock Runs On A Calendar The Market Does Not Set

The stock has stood out while the index has barely moved, but the number that matters for a portfolio is how little of its return comes from the market.

Over the last five trading days, Johnson & Johnson (JNJ) has gained 4.4% while the S&P 500 has slipped 0.5%. The stock sits right at the top of its 52-week range, up 57.3% over the trailing twelve months, and the pull to chase strength like that is real. What decides whether it belongs in your portfolio is not next week’s move, but how much of that return is the company’s own story rather than the index you already own.

What A 0.16 Correlation Bought Over Five Years

Over the past five years, the stock’s correlation to the S&P 500 has been 0.16, on a scale where 1.0 would mean perfect lockstep. A reading that low means the stock largely moves independently of the broad market, which is the defining trait of a genuine diversifier. Over this full five-year horizon, that independence came with a familiar trade-off: an annualized return of 11.8% at 17.5% volatility, compared to 13.2% at 17.2% volatility for the index. Slightly less return for slightly more movement, and little of that return came from the market’s own direction. Nor does the stock duplicate the assets investors normally reach for to get that separation: gold’s correlation to it is 0.05 over the same five years, and real estate’s is 0.35. The stock is a third source of return, not more of either.

STELARA Fell By More Than Half And Sales Still Grew

That independence has a plain business explanation: what moves this company’s revenue is its own product calendar. Management’s framing is that the business does not depend on one or two products, counting 28 platforms that each deliver more than $1 billion in annual sales. Operational sales grew 5.6% in the second quarter of 2026, on worldwide sales of $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and, by the company’s account, now leads new-patient starts in both ulcerative colitis and Crohn’s disease. Revenue durability of that kind – growth delivered while one of its own products is being eroded by biosimilars – is one of the things the Trefis High Quality Portfolio insists on in its holdings.

Over The Past Year It Rose When The Market Fell

On days the S&P 500 rose over the past year, the stock captured only about 1% of the market’s gain; on the days the market fell, the stock moved about 65% in the opposite direction, rising by that share of the decline rather than falling with it. That is a one-year reading, and it can shift, but it describes a holding that leans against an index fund rather than doubling it up. So the role is a differentiated return stream on its own clock, and the risks run on that clock too. One of them is heart recovery, where Abiomed sales fell 2% in the second quarter of 2026 after physicians turned more selective following a neutral clinical trial in the U.K. Owning it with open eyes also means watching what the options market is pricing for the year ahead.

Is Your Biggest Position Undoing Your Diversification?

Diversification is the rare free lunch in investing, and the hardest part is applying it to a position that has already grown large. A position that has grown large enough to matter is worth sizing deliberately rather than by accident. What a position that size would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.